Investor Presentaiton
Investor presentation
Full year 2018
Slide 101
Novo Nordisk maintains leadership within growth disorder
Development in global growth disorder market
DKK
billion
20
15
10-
5
0
Nov
2013
-
MAT volume kg
CAGR volume¹: 17.7%
CAGR value DKK¹: 13.3%
1 CAGR for 5-year period
Source: IQVIA monthly MAT Nov, 2018 volume figures and value figures
changing
diabetes
Growth disorder volume market share
MAT value
kg
120
50%
100
40%
80
30%
+60
20%
40
10%
20
0
0%
Nov
2018
Nov
2013
Novo Nordisk
Eli Lilly
Pfizer
Merck Kgaa
Sandoz
-
Other¹
Source: IQVIA monthly MAT Nov, 2018 volume figures
Note: Does not add up to 100% due to rounding
1 'Other' consists of more than 20 other companies with no single company holding more
than 9% volume market share
27%
26%
15%
14%
9%
9%
Nov
2018
novo nordiskView entire presentation